Inspire Pharmaceuticals (ISPH) says its second Phase 3 clinical trial with Denufosol for cystic...

|About: Inspire Pharmaceuticals,... (ISPH)|By:, SA News Editor

Inspire Pharmaceuticals (ISPH) says its second Phase 3 clinical trial with Denufosol for cystic fibrosis didn't achieve statistical significance for its primary efficacy endpoint. The company calls the results 'disappointing and unexpected.' Shares -55.4% to $3.75. (PR)